CCM
VRTX icon

Coldstream Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Coldstream Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Sell
6,151
-386
-6% -$171K 0.04% 213
2026
Q1 		$2.92M Buy
6,537
+535
+9% +$249K 0.04% 208
2025
Q4 		$2.72M Sell
6,002
-404
-6% -$174K 0.04% 217
2025
Q3 		$2.51M Buy
6,406
+532
+9% +$222K 0.03% 242
2025
Q2 		$2.62M Buy
5,874
+711
+14% +$328K 0.04% 222
2025
Q1 		$2.5M Buy
5,163
+267
+5% +$124K 0.05% 208
2024
Q4 		$1.97M Buy
4,896
+122
+3% +$56.6K 0.04% 246
2024
Q3 		$2.23M Buy
4,774
+552
+13% +$265K 0.05% 213
2024
Q2 		$1.98M Buy
4,222
+253
+6% +$110K 0.05% 210
2024
Q1 		$1.66M Buy
3,969
+38
+1% +$16.1K 0.04% 235
2023
Q4 		$1.6M Buy
3,931
+231
+6% +$85.3K 0.04% 216
2023
Q3 		$1.29M Buy
3,700
+86
+2% +$30.1K 0.04% 234
2023
Q2 		$1.27M Buy
3,614
+40
+1% +$13.5K 0.04% 237
2023
Q1 		$1.13M Buy
3,574
+209
+6% +$62.7K 0.04% 258
2022
Q4 		$972K Buy
+3,365
New +$1.03M 0.04% 271
2022
Q2 		$874K Buy
3,100
+473
+18% +$127K 0.03% 256
2022
Q1 		$686K Buy
2,627
+58
+2% +$13.8K 0.02% 296
2021
Q4 		$564K Buy
2,569
+1,212
+89% +$236K 0.02% 383
2021
Q3 		$369K Buy
1,357
+260
+24% +$50.8K 0.02% 286
2021
Q2 		$221K Buy
1,097
+28
+3% +$5.86K 0.01% 481
2021
Q1 		$230K Sell
1,069
-280
-21% -$61.5K 0.01% 390
2020
Q4 		$319K Buy
1,349
+215
+19% +$49.3K 0.02% 273
2020
Q3 		$308K Buy
1,134
+5
+0.4% +$1.38K 0.03% 234
2020
Q2 		$327K Buy
1,129
+20
+2% +$5.42K 0.03% 220
2020
Q1 		$263K Buy
1,109
+159
+17% +$36.5K 0.03% 220
2019
Q4 		$208K Buy
+950
New +$192K 0.02% 326

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Coldstream Capital Management's VRTX Position: Q2 2026 in Review

Coldstream Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.9% in Q2 2026, selling an estimated $171K and leaving 6,151 shares worth $3.06M. The position accounts for 0.04% of the portfolio, ranked #213.

Coldstream Capital Management first reported a position in VRTX in Q4 2019 and has held it in 26 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Coldstream Capital Management held 6,151 shares of Vertex Pharmaceuticals worth $3.06M as of Q2 2026.
  • Coldstream Capital Management sold 386 Vertex Pharmaceuticals shares in Q2 2026, an estimated $171K.
  • Vertex Pharmaceuticals made up 0.04% of Coldstream Capital Management's portfolio in Q2 2026, its #213 holding.
  • Coldstream Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.